Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

Leukemia Research

Volumn 35, Issue 3, 2011, Pages 380-386

  Qian, Zhengzi ^a,b   Zhang, Liang ^a   Cai, Zhen ^b,c   Sun, Luhong ^c   Wang, Huaqing ^b   Yi, Qing ^a   Wang, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Combination therapy; Dexamethasone; Lenalidomide; Mantle cell lymphoma

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 9; DEXAMETHASONE; LENALIDOMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MANTLE CELL LYMPHOMA; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEXAMETHASONE; DRUG SYNERGISM; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MICE; MICE, SCID; THALIDOMIDE;

EID: 79952106893     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.09.027     Document Type: Article

References (26)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
2. Bosch F., Lopez-Guillermo A., Campo E., Ribera J.M., Conde E., Piris M.A., et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567-575.
3. Campo E., Raffeld M., Jaffe E.S. Mantle-cell lymphoma. Semin Hematol 1999, 36:115-127.
4. Zhou Y., Wang H., Fang W., Romaguer J.E., Zhang Y., Delasalle K.B., et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008, 113:791-798.
5. World health organization classification of tumours. pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001, 189-230. IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
6. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
7. Romaguera J.E., Fayad L., Rodriguez M.A., Broglio K.R., Hagemeister F.B., Pro B., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013-7023.
8. Lenz G., Dreyling M., Hoster E., Wörmann B., Dührsen U., Metzner B., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992.
9. Khouri I.F., Saliba R.M., Okoroji G.J., Acholonu S.A., Champlin R.E. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003, 98:2630-2635.
10. Crane E., List A. Immunomodulatory drugs. Cancer Invest 2005, 23:625-634.
11. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
12. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
13. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
14. Lentzsch S., LeBlanc R., Podar K., Davies F., Lin B., Hideshima T., et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003, 17:41-44.
15. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008, 26:1544-1552.
16. Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106:4050-4053.
17. Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
18. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
19. Habermann T.M., Lossos I.S., Justice G., Vose J.M., Wiernik P.H., McBride K., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
20. Damaj G., Lefrere F., Delarue R., Varet B., Furman R., Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003, 17:1914-1915.
21. Dredge K., Horsfall R., Robinson S.P., Zhang L.H., Lu L., Tang Y., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005, 69:56-63.
22. Dredge K., Marriott J.B., Macdonald C.D., Man H.W., Chen R., Muller G.W., et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002, 87:1166-1172.
23. Hernandez-Ilizaliturri F.J., Reddy N., Holkova B., Ottman E., Czuczman M.S. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005, 11:5984-5992.
24. Chanan-Khan A., Porter C.W. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 2006, 7:480-488.
25. Gandhi A.K., Kang J., Naziruddin S., Parton A., Schafer P.H., Stirling D.I. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006, 30:849-858.
26. Verhelle D., Corral L.G., Wong K., Mueller J.H., Moutouh-de Parseval L., et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67:746-755.